PharmaSGP Holding Future Growth

PharmaSGP Holding is forecast to grow earnings and revenue by 12.3% and 6.8% per annum respectively while EPS is expected to grow by 13.3% per annum.

12.3%

Earnings growth rate

13.3%

EPS growth rate

Pharmaceuticals earnings growth	16.3%
Revenue growth rate	6.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	14 Jun 2024

No updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:PSGD - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	128	25	N/A	35	2
12/31/2025	119	22	30	31	2
12/31/2024	110	20	30	33	2
3/31/2024	107	18	26	28	N/A
12/31/2023	101	16	26	27	N/A
9/30/2023	98	15	25	26	N/A
6/30/2023	94	14	22	23	N/A
3/31/2023	89	13	28	28	N/A
12/31/2022	86	12	24	25	N/A
9/30/2022	83	11	34	35	N/A
6/30/2022	81	11	-64	19	N/A
3/31/2022	74	11	-71	12	N/A
12/31/2021	65	11	-71	12	N/A
9/30/2021	61	8	-89	-6	N/A
6/30/2021	56	8	8	8	N/A
3/31/2021	59	9	12	13	N/A
12/31/2020	63	11	15	15	N/A
9/30/2020	65	16	18	19	N/A
6/30/2020	65	17	17	18	N/A
3/31/2020	64	17	20	20	N/A
12/31/2019	63	17	17	18	N/A
12/31/2018	61	15	8	8	N/A
12/31/2017	53	12	N/A	14	N/A

Earnings vs Savings Rate: PSGD's forecast earnings growth (12.3% per year) is above the savings rate (1.8%).

Earnings vs Market: PSGD's earnings (12.3% per year) are forecast to grow slower than the UK market (12.5% per year).

High Growth Earnings: PSGD's earnings are forecast to grow, but not significantly.

Revenue vs Market: PSGD's revenue (6.8% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: PSGD's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Future ROE: Insufficient data to determine if PSGD's Return on Equity is forecast to be high in 3 years time